Sugi Predict

Sugi Predict / Compounds / SCHEMBL539900

SCHEMBL539900

SCHEMBL539900

CC(C)(C)OC(=O)N1C(=O)CC2CC21

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ NR1H2 P55055 1/20 0.41
▸ GPR119 Q8TDV5 5/20 0.35
▸ KLK7 P49862 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ PREP P48147 1/20 0.35
▸ HSD11B1 P28845 1/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30918718 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL30918715 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL20929429 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL20929165 0.85 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL3741129 0.85 CHRM2 (0.48) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL3733204 0.83 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL3733352 0.83 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL483259 0.77 CHRM2 (0.43) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL20406585 0.77 CHRM2 (0.43) CHRM2CHRM1CHRM3NR1H2GPR119
SCHEMBL26663232 0.76 CHRM2 (0.47) CHRM2CHRM1CHRM3NR1H2KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072451-A1 RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES VIVIDION THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
WO-2024123967-A1 SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS SENYA PHARMACEUTICALS, INC. (US) 2024-06-13 — — WO disclosed
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2024-04-11 — — US disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 — — EP disclosed
WO-2023116877-A1 HETEROCYCLIC COMPOUND AS TEAD INHIBITOR 武汉人福创新药物研发中心有限公司 2023-06-29 — — WO disclosed
WO-2023116877-A1 HETEROCYCLIC COMPOUND AS TEAD INHIBITOR 武汉人福创新药物研发中心有限公司 2023-06-29 — — WO disclosed
CN-116332922-A Heterocyclic compounds as TEAD inhibitors 武汉人福创新药物研发中心有限公司 2023-06-27 — — CN disclosed
CN-109641894-B 2-azabicyclo [3.1.0] hex-3-one derivatives and methods of use 豪夫迈·罗氏有限公司 2022-09-09 — — CN disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
US-20100249190-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-09-30 — — US disclosed
US-20100249190-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-09-30 — — US disclosed
US-20100068176-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-03-18 — — US disclosed
US-20090281331-A1 METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-12 — — US disclosed
WO-2009102325-A1 IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 — — WO disclosed
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 — — US disclosed
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-03-12 — — US disclosed
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-03-12 — — US disclosed
EP-2014648-A1 PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF Sumitomo Chemical Company, Limited (JP) 2009-01-14 — — EP disclosed
EP-2008999-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2008-12-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068176-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, FGFR2, ERBB3 CHRM2 4424/4885CHRM1 4653/4885CHRM3 4743/4885
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885
US-20090281331-A1 METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF C9, NPPA, ADH1C CHRM2 1427/4885CHRM1 1013/4885CHRM3 2751/4885
US-20100249190-A1 Hepatitis C Virus Inhibitors HAVCR2, EIF2AK2, MAVS CHRM2 4839/4885CHRM1 4819/4885CHRM3 4737/4885
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF TERT, CBR1, TELO2 CHRM2 1573/4885CHRM1 622/4885CHRM3 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.